View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

About ZOMETA
Prostate Cancer
Threat of SREs

Page

1 2

As new treatments extend survival, the threat of SREs increases

For patients with good performance status and metastatic disease confined to the axial skeleton, median survival is more than 4 years⁴
Without treatment, the median time to first SRE in men with bone metastases from prostate cancer is less than 11 months²

Median time to first SRE vs median survival in advanced prostate cancer^2,4

*Median survival in men with good performance status and disease
confined to bone that affects the axial skeleton (treatment regimen
not specified).

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.